ORIONS Money Stocks

[Covid19freak]

UNCY $1 next bio bomb about to explode has an attractive kidney treatment near final data readout expected next quarter has low valution of $34 million and over 5 million shares acquired by institutional investors in last weeks .

“OLC’s novel characteristics have the potential to make it the best-in-class phosphate binder in the billion-dollar hyperphosphatemia market. Data from this pivotal trial is the last major component to complete our data package to file a New Drug Application (NDA) and will be informative for physicians as they consider a new potential therapy for their patients. We expect to report data from the trial in the second quarter of 2024 and file the NDA shortly thereafter.”